ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -4 مورد

Terbinafine (systemic): Pediatric drug information

Terbinafine (systemic): Pediatric drug information
2025© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Terbinafine (systemic): Drug information" and "Terbinafine (systemic): Patient drug information"

For abbreviations, symbols, and age group definitions show table
Brand Names: Canada
  • APO-Terbinafine;
  • Auro-Terbinafine;
  • DOM-Terbinafine [DSC];
  • LamISIL [DSC];
  • PMS-Terbinafine;
  • RIVA-Terbinafine [DSC];
  • Terbinafine-250;
  • TEVA Terbinafine
Therapeutic Category
  • Antifungal Agent, Oral
Dosing: Pediatric
Onychomycosis

Onychomycosis: Limited data available (Ref): Children and Adolescents:

10 to 20 kg: Oral: 62.5 mg once daily for 6 weeks (fingernails) or 12 weeks (toenails).

>20 to 40 kg: Oral: 125 mg once daily for 6 weeks (fingernails) or 12 weeks (toenails).

>40 kg: Oral: 250 mg once daily for 6 weeks (fingernails) or 12 weeks (toenails).

Tinea capitis

Tinea capitis: Limited data available: Note: Preferred treatment agent varies based on causative pathogen (known or suspected). For infections caused by Trichophyton tonsurans (~95% of cases in the United States), terbinafine is considered superior to griseofulvin (Ref). For Microsporum spp. infections, griseofulvin is preferred over terbinafine. If terbinafine is used for Microsporum infections, higher-dose regimens are preferred (Ref).

Standard-dose regimen:

Children and Adolescents: Note: Dosing based on 4 to 6 mg/kg/day (Ref)

10 to <20 kg: Oral: 62.5 mg once daily.

20 to 40 kg: Oral: 125 mg once daily.

>40 kg: Oral: 250 mg once daily.

Higher-dose regimen (Ref):

Children and Adolescents:

10 to <25 kg: Oral: 125 mg once daily.

25 to 35 kg: Oral: 187.5 mg once daily.

>35 kg: Oral: 250 mg once daily.

Duration of therapy: Typically ~4 to 6 weeks but may vary based on pathogen and clinical response; Microsporum canis may require treatment for longer duration (eg, up to 12 weeks) (Ref).

Tinea corporis, tinea cruris, and tinea pedis

Tinea corporis (ringworm), tinea cruris (jock itch), and tinea pedis (athlete's foot): Very limited data available: Note: Dosing is extrapolated from tinea capitis treatment studies; oral therapy should be reserved for disease that does not respond to topical therapy or for extensive/severe infection (Ref).

Children and Adolescents: Note: Dosing based on 4 to 6 mg/kg/day (Ref).

10 to <20 kg: Oral: 62.5 mg once daily (Ref).

20 to 40 kg: Oral: 125 mg once daily (Ref).

>40 kg: Oral: 250 mg once daily (Ref).

Duration of therapy: Typically ≥2 weeks (Ref).

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling; however, clearance is decreased ~50% in adult patients with CrCl ≤50 mL/minute.

Dosing: Liver Impairment: Pediatric

There are no pediatric-specific dosage adjustments provided in the manufacturer's labeling; use is contraindicated in adults with chronic or active hepatic disease.

Dosing: Adult

(For additional information see "Terbinafine (systemic): Drug information")

Onychomycosis

Onychomycosis:

Continuous dosing: Oral: 250 mg once daily for 6 weeks (fingernail) or 12 weeks (toenail).

Pulsed dosing (alternative dosing method) (off label):

Note: Optimal dosing regimen not established. Pulsed dosing is less effective than continuous dosing (Ref).

Oral: 250 mg once daily for 4 weeks, off for 4 weeks, then resume with 250 mg once daily for 4 weeks (Ref) or 500 mg/day in 1 or 2 divided doses for 1 week repeated every 4 weeks for 3 months (Ref).

Sporotrichosis, lymphocutaneous and cutaneous

Sporotrichosis, lymphocutaneous and cutaneous (alternative agent for patients who do not respond to itraconazole) (off-label use): Oral: 500 mg twice daily (Ref). Treat for 2 to 4 additional weeks after all lesions have resolved; usual duration is 3 to 6 months (Ref).

Tinea infection

Tinea infection:

Dermatophyte folliculitis (tinea barbae, Majocchi granuloma) (off-label use): Oral: 250 mg once daily; duration is typically 2 to 6 weeks or until clinical resolution (Ref).

Tinea capitis (off-label use): Oral: 250 mg once daily for 4 to 6 weeks (Ref).

Tinea corporis/tinea cruris (alternative agent) (off-label use): Note: For disease that is extensive or refractory to topical therapy (Ref).

Oral: 250 mg once daily for 1 to 2 weeks (Ref).

Tinea pedis/tinea manuum (alternative agent) (off-label use): Note: For disease that is extensive or refractory to topical therapy (Ref).

Oral: 250 mg once daily for 2 weeks (Ref).

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Altered kidney function: Oral:

CrCl ≥50 mL/minute: No dosage adjustment necessary.

CrCl 20 to <50 mL/minute: Administer 50% of the usual dose (Ref).

CrCl <20 mL/minute: Use of alternative agent may be preferred (expert opinion); has not been adequately studied in this population. If necessary, administer 50% of usual dose and monitor frequently for adverse effects (eg, gastrointestinal, hepatic) (Ref).

Hemodialysis, intermittent (thrice weekly): Unlikely to be significantly dialyzed (highly protein bound, large Vd) (Ref):

Oral: Use of alternative agent may be preferred; has not been adequately studied in this population. If necessary, administer 50% of usual dose and monitor frequently for adverse effects (eg, gastrointestinal, hepatic) (Ref).

Peritoneal dialysis: Unlikely to be significantly dialyzed (highly protein bound, large Vd) (Ref):

Oral: Use of alternative agent may be preferred; has not been adequately studied in this population. If necessary, administer 50% of usual dose and monitor frequently for adverse effects (eg, gastrointestinal, hepatic) (Ref).

CRRT: Oral: Use of alternative agent may be preferred; has not been adequately studied in this population. If necessary, administer 50% of usual dose and monitor frequently for adverse effects (eg, gastrointestinal, hepatic) (Ref).

PIRRT (eg, sustained, low-efficiency diafiltration): Oral: Use of alternative agent may be preferred; has not been adequately studied in this population. If necessary, administer 50% of usual dose and monitor frequently for adverse effects (eg, gastrointestinal, hepatic) (Ref).

Dosing: Liver Impairment: Adult

The liver dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Matt Harris, PharmD, MHS, BCPS, FAST, FCCP; Jeong Park, PharmD, MS, BCPS, FCCP, FAST; Arun Jesudian, MD; Sasan Sakiani, MD.

Note : No long-term pharmacokinetic or safety data are available for use in patients with cirrhosis (Ref).

Liver impairment prior to treatment initiation:

Child-Turcotte-Pugh class A to C: Oral: Use is contraindicated (Ref).

Adverse Reactions (Significant): Considerations
Hepatotoxicity

Terbinafine may cause hepatotoxicity (ranging from mild and asymptomatic increased serum transaminases to hepatic failure) (Ref). Terbinafine liver injury may present as hepatocellular hepatitis or cholestatic hepatitis, with some cases progressing to vanishing bile duct syndrome (Ref). Most cases of hepatotoxicity are self-limited; although, persistent and severe hepatocellular injury cases have been reported, requiring discontinuation of therapy or in rare cases liver transplantation (Ref). Resolution may be delayed (eg, 3 to 6 months) following discontinuation of therapy (Ref). Acute hepatic failure due to terbinafine therapy is rare (Ref).

Mechanism: Non–dose-related; possible mechanisms include immunologic (part of a hypersensitivity reaction) or a metabolically mediated effect (formation of mono-GSH conjugate which binds to hepatobiliary proteins (Ref).

Onset: Varied; typically within the first 4 to 6 weeks of therapy (Ref).

Risk factors:

• HLA-A* 33:01 allele (Ref)

Hypersensitivity reactions (delayed)

Severe cutaneous adverse reactions (SCARs), including Stevens Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) (Ref), drug reaction with eosinophilia and systemic symptoms (DRESS) (Ref) and acute generalized exanthematous pustulosis (AGEP) (Ref) have been reported. Other delayed cutaneous reactions include pityriasis rosea (Ref), lichenoid eruptions (Ref), symmetrical drug-related intertriginous and flexural erythema (SDRIFE) (Ref) and subacute cutaneous lupus erythematosus (SCLE) (Ref).

Mechanism: Non–dose-related; immunologic. Delayed hypersensitivity reactions including SCARs are T-cell-mediated (Ref).

Onset: Delayed hypersensitivity reactions: Varied; SCARs usually occur 1 to 8 weeks after initiation (Ref), although AGEP may have a more rapid onset within 2 days (Ross 2018); re-exposure usually results in symptoms within 1 to 4 days (Ref). SCLE generally occurs within 4 to 8 weeks after initiation (Ref).

Risk factors:

• Females (SCLE) (Ref)

• Cross-reactivity: Terbinafine, an allylamine antifungal, is structurally similar to naftifine; although, documented cross-reactivity has not been established. No cross-reactivity between terbinafine and naftifine was noted on patch tests (Ref).

Taste & smell disturbances

Dysgeusia (including ageusia; bitter/sour > salty/sweet) (Ref) and altered sense of smell (including anosmia) may occur and severe cases resulting in decreased food intake, weight loss, anxiety, or depression have been reported. Resolution may be delayed (eg, several weeks to >1 year) following discontinuation of therapy or in some cases, disturbance may be permanent.

Mechanism: Not well known; possible mechanisms include receptor dysfunction through the inhibition of cytochrome P450-dependent enzyme or alteration of the cell structure or function of taste-related neurons through interference of the cholesterol biosynthesis pathway (Ref).

Onset: Delayed; mean onset of taste loss was 35 days (Ref).

Risk factors (taste disturbance):

• Age (>55 years) (Ref)

• History of taste loss (Ref)

• Low body mass index (<21 kg/m2) (Ref)

Thrombotic microangiopathy

Thrombotic microangiopathy (TMA), including thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome, have been reported rarely (some fatal). Recurrent anemia and thrombocytopenia may occur within 2 weeks after discontinuation (Ref).

Mechanism: Non–dose-related; immunologic (anti-ADAMTS-13 antibodies may be increased) (Ref).

Onset: Intermediate; in one case report, occurred within ~2 weeks after therapy initiation (Ref).

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

>10%: Nervous system: Headache (13%)

1% to 10%:

Dermatologic: Pruritus (3%), skin rash (6%), urticaria (1%)

Gastrointestinal: Diarrhea (6%), dysgeusia (3%; may be severe and result in weight loss) (table 1), dyspepsia (4%)

Terbinafine (Systemic): Adverse Reaction: Dysgeusia

Drug (Terbinafine [Systemic])

Placebo

Number of Patients (Terbinafine [Systemic])

Number of Patients (Placebo)

3%

0.7%

465

137

Hepatic: Increased serum transaminases (3%) (table 2)

Terbinafine (Systemic): Adverse Reaction: Increased Serum Transaminases

Drug (Terbinafine [Systemic])

Placebo

Number of Patients (Terbinafine [Systemic])

Number of Patients (Placebo)

3%

1%

465

137

Postmarketing:

Cardiovascular: Vasculitis

Dermatologic: Acute generalized exanthematous pustulosis (Ref), alopecia (Ref), bullous dermatitis (Ref), cutaneous lupus erythematosus (Ref), erythema multiforme (Ref), exacerbation of psoriasis (Ref), exfoliative dermatitis (Ref), lichenoid eruption (Ref), pityriasis rosea (Ref), psoriasiform eruption (Ref), skin photosensitivity (Ref), Stevens-Johnson syndrome (Ref), toxic epidermal necrolysis (Ref)

Gastrointestinal: Ageusia (Ref), cholestasis (Ref), pancreatitis, vomiting

Hematologic & oncologic: Agranulocytosis (Ref), anemia (Ref), hemolytic-uremic syndrome, pancytopenia (Ref), severe neutropenia (Ref), thrombocytopenia (Ref), thrombotic microangiopathy (Ref), thrombotic thrombocytopenic purpura (Ref)

Hepatic: Cholestatic hepatitis (Ref), hepatic failure (Ref), hepatic impairment, hepatocellular hepatitis (Ref)

Hypersensitivity: Anaphylaxis, angioedema, drug reaction with eosinophilia and systemic symptoms (Ref), serum sickness-like reaction

Nervous system: Altered sense of smell (Ref), anosmia (Ref), anxiety, depression, fatigue, hypoesthesia, malaise, paresthesia, vertigo

Neuromuscular & skeletal: Arthralgia, exacerbation of systemic lupus erythematosus (Ref), increased creatine phosphokinase in blood specimen, myalgia, rhabdomyolysis (Ref), systemic lupus erythematosus (Ref)

Ophthalmic: Decreased visual acuity, visual field defect

Otic: Auditory impairment, tinnitus

Respiratory: Flu-like symptoms

Miscellaneous: Fever

Contraindications

Hypersensitivity to terbinafine or any component of the formulation; chronic or active hepatic disease

Warnings/Precautions

Concerns related to adverse effects:

• Allylamine antifungal hypersensitivity: Use caution in patients sensitive to allylamine antifungals (eg, naftifine, butenafine); cross-sensitivity to terbinafine may exist.

• Ocular effects: Although rare, changes in the ocular lens and retina have been reported; discontinuation of therapy may be required.

Disease-related concerns:

• Autoimmune disease (Lupus): Precipitation or exacerbation of cutaneous or systemic lupus erythematosus has been observed; discontinue if signs and/or symptoms develop.

• Hepatic impairment: Use is contraindicated in patients with active or chronic hepatic disease; clearance is reduced by ~50% in hepatic cirrhosis.

• Renal impairment: Use with caution in patients with renal dysfunction (CrCl ≤50 mL/minute); clearance is reduced by ~50%.

Other warnings/precautions:

• Appropriate use: Due to potential toxicity, confirmation of diagnostic testing of nail or skin specimens prior to treatment of onychomycosis or dermatomycosis is recommended.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Generic: 250 mg

Generic Equivalent Available: US

Yes

Pricing: US

Tablets (Terbinafine HCl Oral)

250 mg (per each): $12.67 - $13.02

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Tablet, Oral:

LamISIL: 250 mg [DSC]

Generic: 250 mg

Extemporaneous Preparations

25 mg/mL Oral Suspension:

A 25 mg/mL oral suspension may be made using tablets. Crush twenty 250 mg tablets and reduce to a fine powder. Add small amount of a 1:1 mixture of Ora-Sweet and Ora-Plus and mix to a uniform paste; mix while adding the vehicle in geometric proportions to almost 200 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 200 mL. Label "shake well" and "refrigerate". Stable 42 days.

Nahata MC, Pai VB, and Hipple TF, Pediatric Drug Formulations, 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.
Administration: Pediatric

Oral: Tablets: Administer without regard to meals.

Administration: Adult

Oral: Administer without regard to meals.

Storage/Stability

Store below 25°C (77°F). Protect from light.

Medication Guide and/or Vaccine Information Statement (VIS)

An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:

Lamisil: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020539s033lbl.pdf#page=11

Use

Treatment of onychomycosis of the toenail or fingernail due to susceptible dermatophytes (FDA approved in adults); has also been used in the treatment of tinea capitis, tinea corporis, tinea cruris, and tinea pedis.

Medication Safety Issues
Sound-alike/look-alike issues:

Terbinafine may be confused with terbutaline

LamISIL may be confused with LaMICtal, Lomotil

Metabolism/Transport Effects

Substrate of CYP1A2 (Minor), CYP2C19 (Minor), CYP2C9 (Minor), CYP3A4 (Minor); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; Inhibits CYP2D6 (Moderate);

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program

Ajmaline: CYP2D6 Inhibitors (Moderate) may increase serum concentration of Ajmaline. Risk C: Monitor

Amitriptyline: CYP2D6 Inhibitors (Moderate) may increase serum concentration of Amitriptyline. CYP2D6 Inhibitors (Moderate) may increase active metabolite exposure of Amitriptyline. Risk C: Monitor

Amoxapine: CYP2D6 Inhibitors (Moderate) may increase serum concentration of Amoxapine. Risk C: Monitor

Amphetamines: CYP2D6 Inhibitors (Moderate) may increase serum concentration of Amphetamines. Management: Monitor for amphetamine toxicities (including serotonin syndrome) if used with a moderate CYP2D6 inhibitor. Initiate amphetamine therapy at lower doses, monitor frequently, and adjust doses as needed. Discontinue amphetamines if serotoinin syndrome occurs Risk C: Monitor

ARIPiprazole Lauroxil: CYP2D6 Inhibitors (Moderate) may increase active metabolite exposure of ARIPiprazole Lauroxil. Risk C: Monitor

ARIPiprazole: CYP2D6 Inhibitors (Moderate) may increase serum concentration of ARIPiprazole. Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy, indication, or dosage form. Consult full interaction monograph for specific recommendations. Risk C: Monitor

Atomoxetine: CYP2D6 Inhibitors (Moderate) may increase serum concentration of Atomoxetine. Risk C: Monitor

Brexpiprazole: CYP2D6 Inhibitors (Moderate) may increase serum concentration of Brexpiprazole. Management: If brexpiprazole is to be used together with both a moderate CYP2D6 inhibitor and a strong or moderate CYP3A4 inhibitor, the brexpiprazole dose should be reduced to 25% of the usual dose when treating indications other than major depressive disorder. Risk C: Monitor

Carvedilol: CYP2D6 Inhibitors (Moderate) may increase serum concentration of Carvedilol. Risk C: Monitor

ClomiPRAMINE: CYP2D6 Inhibitors (Moderate) may increase serum concentration of ClomiPRAMINE. CYP2D6 Inhibitors (Moderate) may increase active metabolite exposure of ClomiPRAMINE. Risk C: Monitor

CloZAPine: CYP2D6 Inhibitors (Moderate) may increase serum concentration of CloZAPine. Risk C: Monitor

Codeine: CYP2D6 Inhibitors (Moderate) may decrease therapeutic effects of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine. Risk C: Monitor

CycloSPORINE (Systemic): Terbinafine (Systemic) may decrease serum concentration of CycloSPORINE (Systemic). Risk C: Monitor

Desipramine: CYP2D6 Inhibitors (Moderate) may increase serum concentration of Desipramine. Risk C: Monitor

Deutetrabenazine: CYP2D6 Inhibitors (Moderate) may increase active metabolite exposure of Deutetrabenazine. Risk C: Monitor

Dextromethorphan: CYP2D6 Inhibitors (Moderate) may increase serum concentration of Dextromethorphan. Risk C: Monitor

Doxepin (Systemic): CYP2D6 Inhibitors (Moderate) may increase serum concentration of Doxepin (Systemic). Risk C: Monitor

Doxepin (Topical): CYP2D6 Inhibitors (Moderate) may increase serum concentration of Doxepin (Topical). Risk C: Monitor

DOXOrubicin (Conventional): CYP2D6 Inhibitors (Moderate) may increase serum concentration of DOXOrubicin (Conventional). Risk X: Avoid

Eliglustat: CYP2D6 Inhibitors (Moderate) may increase serum concentration of Eliglustat. Management: Eliglustat dose is 84 mg daily with CYP2D6 inhibitors. Use is contraindicated (COI) when also combined with strong CYP3A4 inhibitors. When also combined with a moderate CYP3A4 inhibitor, use is COI in CYP2D6 EMs or IMs and should be avoided in CYP2D6 PMs. Risk D: Consider Therapy Modification

Flecainide: CYP2D6 Inhibitors (Moderate) may increase serum concentration of Flecainide. Risk C: Monitor

Haloperidol: CYP2D6 Inhibitors (Moderate) may increase serum concentration of Haloperidol. Risk C: Monitor

Iboga: CYP2D6 Inhibitors (Moderate) may increase serum concentration of Iboga. Risk C: Monitor

Iloperidone: CYP2D6 Inhibitors (Moderate) may increase serum concentration of Iloperidone. CYP2D6 Inhibitors (Moderate) may decrease active metabolite exposure of Iloperidone. Specifically, concentrations of the metabolite P95 may be decreased. CYP2D6 Inhibitors (Moderate) may increase active metabolite exposure of Iloperidone. Specifically, concentrations of the metabolite P88 may be increased. Risk C: Monitor

Imipramine: CYP2D6 Inhibitors (Moderate) may increase active metabolite exposure of Imipramine. Concentrations of desipramine may be increased. CYP2D6 Inhibitors (Moderate) may increase serum concentration of Imipramine. Risk C: Monitor

Indoramin: CYP2D6 Inhibitors (Moderate) may increase serum concentration of Indoramin. Risk C: Monitor

Lofepramine: CYP2D6 Inhibitors (Moderate) may increase active metabolite exposure of Lofepramine. The active metabolite of lofepramine is desipramine. Risk C: Monitor

Mequitazine: CYP2D6 Inhibitors (Moderate) may increase serum concentration of Mequitazine. Risk X: Avoid

Methadone: CYP2D6 Inhibitors (Moderate) may increase serum concentration of Methadone. Risk C: Monitor

Metoclopramide: CYP2D6 Inhibitors (Moderate) may increase serum concentration of Metoclopramide. Risk C: Monitor

Metoprolol: CYP2D6 Inhibitors (Moderate) may increase serum concentration of Metoprolol. Risk C: Monitor

Nebivolol: CYP2D6 Inhibitors (Moderate) may increase serum concentration of Nebivolol. Risk C: Monitor

Nortriptyline: CYP2D6 Inhibitors (Moderate) may increase serum concentration of Nortriptyline. Risk C: Monitor

Oliceridine: CYP2D6 Inhibitors (Moderate) may increase serum concentration of Oliceridine. Risk C: Monitor

Olmutinib: CYP2D6 Inhibitors (Moderate) may increase serum concentration of Olmutinib. Risk C: Monitor

PARoxetine: CYP2D6 Inhibitors (Moderate) may increase serum concentration of PARoxetine. Risk C: Monitor

Perhexiline: CYP2D6 Inhibitors (Moderate) may increase serum concentration of Perhexiline. Risk C: Monitor

Perphenazine: CYP2D6 Inhibitors (Moderate) may increase serum concentration of Perphenazine. Risk C: Monitor

Pimozide: CYP2D6 Inhibitors (Moderate) may increase serum concentration of Pimozide. Risk C: Monitor

Pitolisant: CYP2D6 Inhibitors (Moderate) may increase serum concentration of Pitolisant. Risk C: Monitor

Propafenone: CYP2D6 Inhibitors (Moderate) may increase serum concentration of Propafenone. Risk C: Monitor

Propranolol: CYP2D6 Inhibitors (Moderate) may increase serum concentration of Propranolol. Risk C: Monitor

Protriptyline: CYP2D6 Inhibitors (Moderate) may increase serum concentration of Protriptyline. Risk C: Monitor

RifAMPin: May decrease serum concentration of Terbinafine (Systemic). Risk C: Monitor

RisperiDONE: CYP2D6 Inhibitors (Moderate) may increase serum concentration of RisperiDONE. Risk C: Monitor

Saccharomyces boulardii: Antifungal Agents (Systemic and Oral [Non-Absorbable]) may decrease therapeutic effects of Saccharomyces boulardii. Risk X: Avoid

Sertindole: CYP2D6 Inhibitors (Moderate) may increase serum concentration of Sertindole. Risk C: Monitor

Sofpironium: CYP2D6 Inhibitors (Moderate) may increase serum concentration of Sofpironium. Risk C: Monitor

Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease active metabolite exposure of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites. Management: Consider alternatives to the use of moderate CYP2D6 inhibitors with tamoxifen when possible, as the combination may be associated with reduced clinical effectiveness of tamoxifen. Risk D: Consider Therapy Modification

Tamsulosin: CYP2D6 Inhibitors (Moderate) may increase serum concentration of Tamsulosin. Risk C: Monitor

Tetrabenazine: CYP2D6 Inhibitors (Moderate) may increase active metabolite exposure of Tetrabenazine. Specifically, concentrations of the active alpha- and beta-dihydrotetrabenazine metabolites may be increased. Risk C: Monitor

Thioridazine: CYP2D6 Inhibitors (Moderate) may increase serum concentration of Thioridazine. Risk X: Avoid

Timolol (Systemic): CYP2D6 Inhibitors (Moderate) may increase serum concentration of Timolol (Systemic). Risk C: Monitor

TraMADol: CYP2D6 Inhibitors (Moderate) may increase serum concentration of TraMADol. CYP2D6 Inhibitors (Moderate) may decrease active metabolite exposure of TraMADol. Risk C: Monitor

Trimipramine: CYP2D6 Inhibitors (Moderate) may increase serum concentration of Trimipramine. Risk C: Monitor

Valbenazine: CYP2D6 Inhibitors (Moderate) may increase active metabolite exposure of Valbenazine. Risk C: Monitor

Vortioxetine: CYP2D6 Inhibitors (Moderate) may increase serum concentration of Vortioxetine. Risk C: Monitor

Zuclopenthixol: CYP2D6 Inhibitors (Moderate) may increase serum concentration of Zuclopenthixol. Risk C: Monitor

Pregnancy Considerations

Published information related to the use of systemic terbinafine in pregnancy is limited (Gupta 1997a; Sarkar 2003).

Systemic therapy for the treatment of onychomycosis or tinea capitis is not recommended during pregnancy (Kaul 2017; Murase 2014).

Monitoring Parameters

AST/ALT prior to initiation, repeat if used >6 weeks; some experts have suggested that repeat testing at 6 weeks is unnecessary (Patel 2017); CBC (if used >6 weeks in immunocompromised patients).

Mechanism of Action

Synthetic allylamine derivative that inhibits squalene epoxidase, a key enzyme in sterol biosynthesis in fungi. This results in a deficiency in ergosterol within the fungal cell membrane and results in fungal cell death.

Pharmacokinetics (Adult Data Unless Noted)

Absorption: >70%.

Distribution: Distributed to sebum and skin predominantly.

Protein binding: Plasma: >99%.

Metabolism: Hepatic predominantly via CYP1A2, 3A4, 2C8, 2C9, and 2C19 to inactive metabolites.

Bioavailability: 40% (as a result of first-pass metabolism).

Half-life elimination: Terminal half-life: 200 to 400 hours; very slow release of drug from skin and adipose tissues occurs.

Effective half-life:

Children 5 to 11 years: 14.7 ± 4.3 hours (range: 9.8 to 25.7 hours) (Humbert 1998; Nejjam 1995).

Adults: ~36 hours.

Time to peak, plasma: Children and Adults: Within 2 hours (Abdel-Rahman 2005; manufacturer's labeling).

Excretion: Urine (80%, primarily as inactive metabolites); feces (20%) (Debruyne 2001).

Clearance:

Children 4 to 8 years: 1.41 ± 2.5 L/hour/kg (Abdel-Rahman 2005).

Adults: 0.47 ± 0.21 L/hour/kg (Abdel-Rahman 2005).

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Altered kidney function: In CrCl ≤50 mL/minute, terbinafine clearance is decreased 50%.

Hepatic function impairment: Clearance is decreased 30% to 50% (Balfour 1992; Jensen 1989; manufacturer's labeling).

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Lamifen | Lamisil | Negafen | Onchofin;
  • (AR) Argentina: Fungueal | Lamisil | Likana | Tacna | Terbinafina richet | Terekol;
  • (AT) Austria: Amisan | Amykal | Lamisil | Myconafin | Terbiderm | Terbinafin actavis;
  • (AU) Australia: Apo terbinafine | Genrx Terbinafine | Lamisil | Noumed terbinafine | Pharmacor Terbinafine | Sebifin | Tamsil | Terbihexal | Terbinafine | Terbinafine Actavis | Terbinafine an | Terbinafine Ga | Terbinafine sandoz | Terbix | Tinasil | Zabel;
  • (BD) Bangladesh: Derfin | Elvina | Infud | Mycocure | Mycofin | Mycofree | Skinabin | Terbex | Terbicare | Terbicon | Terbiderm | Terbifin | Terbikill | Terbimax | Terbinox | Xfin;
  • (BE) Belgium: Doc Terbinafine | Lamisil | Terbinafin ab | Terbinafine apotex | Terbinafine Aurobindo | Terbinafine EG | Terbinafine sandoz | Terbinafine teva;
  • (BF) Burkina Faso: Onycal;
  • (BG) Bulgaria: Fungofin | Lamisil | Myconafine | Terbinafin | Ternafin;
  • (BR) Brazil: Ceremil | Cloridrato de terbinafina | Funtyl | Lamisil | Tertop | Zior;
  • (CH) Switzerland: Lamisil | Onymax | Terbifil | Terbinafin actavis | Terbinafin Axapharm | Terbinafin Helvepharm | Terbinafin teva | Terbinafin zentiva | Terbinax | Tineafin;
  • (CI) Côte d'Ivoire: Onycal;
  • (CL) Chile: Dermoxyl | Dicil | Donter | Elater | Farbicil | Finex | Fungra | Lamisil | Micoset | Mucivil | Terbinafina | Terfex;
  • (CN) China: Bei jia | Ding ke | Lamisil | Lan mei shu;
  • (CO) Colombia: Bellex | Enisol | Farbicil | Filut | Funide | Funzal | Hongoderm | Incomic | K Micot | Kew | Lamicol | Lamisil | Terbiderm | Terbinafina | Tersag;
  • (CZ) Czech Republic: Lamisil | Onychon | Terbinafin actavis | Terbinafin teva | Terbisil | Terfimed;
  • (DE) Germany: Amiada | Dermatin | Lamisil | Myconormin | Onymax | Terbiderm | Terbigalen | Terbina Q | Terbinafin | Terbinafin Acis | Terbinafin AL | Terbinafin Beta | Terbinafin CT | Terbinafin Dura | Terbinafin Heumann | Terbinafin hexal | Terbinafin Kwizda | Terbinafin pfizer | Terbinafin puren | Terbinafin q-pharm | Terbinafin sandoz | Terbinafin Stada | Terbinafin teva | Terbinafin Winthrop | Terbinafin-1 A Pharma | Terbinafin-isis | Terbinafine Aurobindo;
  • (DK) Denmark: Lamisil | Terbinafin 1a farma | Terbinafin hexal;
  • (DO) Dominican Republic: Farbicil | Fungoter | Lamisil | Micostop | Mycelvan | Nafin | Terekol;
  • (EC) Ecuador: Dermoxil | Dermoxyl | Dicil | Donter | Exifine | Finex | Fungistat | Funide | Lamidizol | Lamisil | Micostop | Micoxial | Micozone | Terbifung | Terbilazar | Terbinachem | Terbinafina | Terbinafina mk | Terbinafina nifa | Terbinox | Terbisil | Terbix | Terfin | Terfinamed | Vardenil;
  • (EE) Estonia: Lamisil | Terbinafin | Terbinafin actavis | Terbinafin sandoz | Terbinafine Olainfarm | Terbinafine sandoz | Terbinafine terbano | Terbisil | Terbisil kid;
  • (EG) Egypt: Fungisafe | Lamifen | Lamisil | Mycomic | Terbifungin | Terbin | Terbinasil | Trerbi;
  • (ES) Spain: Fungicare | Lamisil | Talixane | Terbinafina Alter | Terbinafina Aurobindo | Terbinafina aurovitas | Terbinafina Combix | Terbinafina Kern Pharma | Terbinafina Normon | Terbinafina Pensa | Terbinafina pharmacia | Terbinafina Teva;
  • (ET) Ethiopia: Lamisil;
  • (FI) Finland: Lamisil | Terbinafiini Enna | Terbinafin alternova | Terbinafin Bmm Pharma | Terbinafin Galderma | Terbinafin hexal | Terbinafin pfizer | Terbinafin Ratiopharm;
  • (FR) France: Fungster | Terbinafine Actavis | Terbinafine almus | Terbinafine Alter | Terbinafine Arrow | Terbinafine bailleul | Terbinafine biogaran | Terbinafine Cristers | Terbinafine EG | Terbinafine evolugen | Terbinafine Isomed | Terbinafine pfizer | Terbinafine qualimed | Terbinafine ranbaxy | Terbinafine ratiopharm | Terbinafine RPG | Terbinafine sandoz | Terbinafine zydus;
  • (GB) United Kingdom: Lamisil | Terbinafine | Terbinafine relonchem;
  • (GR) Greece: Chemiderm | Funger | Lamisil | Terbafin | Terbinafine Aurobindo | Terbinafine/Target | Terfinor | Terilam | Termisil | Ternafinol | Thateron | Zakofin;
  • (HK) Hong Kong: Apo terbinafine | Erbinol | Jmp terbinafine | Lamisil | Synbinafine | Tebinisil | Terbifin | Terbinafina Farmoz | Terbinafine Actavis | Terbinafine teva | Terfung;
  • (HR) Croatia: Lamisil | Terbinafin JGL | Terbinax | Verbinaf;
  • (HU) Hungary: Lamigard | Lamisil | Terbigen | Terbinafin Ratiopharm | Terbinafine pfizer | Terbinafine q pharma | Terbiner | Terbisil | Tineal;
  • (ID) Indonesia: Interbi;
  • (IE) Ireland: Fungafine | Fungasil | Lamater | Lamisil | Lanafine | Nailderm | Terbasil | Terbinafine rowa | Ternaf;
  • (IL) Israel: Lamisil | Terbinafine;
  • (IN) India: Acbro | Af-ter | Alnabin | Bdterbin | Daskil | Elifin | Exifine | Finecure | Finlin | Fintrix | Fungixit t | Fungotek | Funter | Hifen | Ifin | Keptafine | Lamisil | Lamiterb | Micoside | Mycosol | Phyte | Sebifin | Sinofin | Skitofine | Tebif | Tebina | Tebisure | Teraderm | Terbest | Terbicip | Terbicutis | Terbidor | Terbifix | Terbiforce | Terbikem | Terbimax | Terbin | Terbinaforce | Terbinator | Terbinax | Terbinext | Terbiroz | Terbitotal | Terbivolt | Terbized | Terbocet | Terbofin | Terbol | Terbotac | Terfast | Terfaze | Terfitis | Terfung | Tergosil | Tersig | Texifen | Tinafine | Tinafix | Topcos | Trfy | Turfine | Tyza | Zimig | Zoterb | Zygter;
  • (IT) Italy: Daskil | Lamisil | Micutan | Onymax | Terbinafina | Terbinafina Arrow | Terbinafina Aurobindo | Terbinafina Doc | Terbinafina EG | Terbinafina Mgi | Terbinafina San | Terbinafina sandoz | Terbinafina tecnigen;
  • (JO) Jordan: Lamisil | Terfinil | Tinasil;
  • (JP) Japan: Lamisil | Lipnol | Nedoril | Ramitect | Tebinaceil | Terbinafine | Terbinafine hydrochloride f | Terbinafine pfizer | Terbinal | Terby | Terfinabine | Termisil;
  • (KE) Kenya: Finamark | Fungisil | Fungiter | Lamifen | Lamisil | Mycofin | Oncosil | Skinabin | Tebif | Terbex | Terbifin | Terbin | Terbinaforce | Terbinol | Terbisil | Terbitack;
  • (KR) Korea, Republic of: Bacxil | Berafine | Binasil | Cellnafine | Celtenafin | Cinafine | Curasil | Demisil | Dongsung terbinafine | Ernafin | Inno.n terbinafine hcl | Jw terbinafine | Lamipin | Lamisil | Lamitin | Lamonan | Laniten | Lapiderm | Lespo | Limecin | Lonasil | M ternafine | Micosil | Mujonal | Namuzole | Natocil | Ramiguard | Ramihu | Raminafine | Ronacil | Samsung terbinafine | Selbina | Selnapin | Sentoes | Seoul terbinafine hci | Tabianfine | Tabinafine | Tbf | Tebafine | Tebina | Tebisil | Telbina | Temisil | Tenabin | Tenavine | Terbi | Terbiclin | Terbifine | Terbigen | Terbil | Terbin | Terbina | Terbinafine | Terbinafine HCL | Terbinafine ss | Terbinarin | Terbinex | Terbini | Termina | Terna | Ternabi | Ternabin | Ternarine | Terpin m | Terzol | Uninapin;
  • (KW) Kuwait: Exifine | Lamifen | Lamisil;
  • (LB) Lebanon: Apo terbinafine | Boderm | Lamifen | Laminox | Lamisil | Terafan;
  • (LT) Lithuania: Exifine | Lamisil | Terbinafin actavis | Terbinafin bijon | Terbinafin sandoz | Terbinafine Actavis | Terbinafine Bmm | Terbinafine sandoz | Terbisil | Terbisil kid;
  • (LU) Luxembourg: Doc Terbinafine | Lamisil;
  • (LV) Latvia: Lamisil | Terbinafine Olainfarm | Terbisil | Terbisil kid;
  • (MA) Morocco: Lifongid | Onifine | Teguma | Terbinafine Gt | Terfine | Terix;
  • (MX) Mexico: Abinifin | Allifort | Bifynason's | Binafex | Erbitrax | Erbitrax t | Fyterdin | Hudiclor | Lamisil | Losil t | Losil T | Mycelvan | Terbinafina | Terlisgen | Unasal;
  • (MY) Malaysia: Apo terbinafine | Exifine | Lamisil | Lisim | Onchofin | Terbicip | Terbinafine Cadila | Ternafin;
  • (NG) Nigeria: Multichris terbinafine | Terbinaforce;
  • (NL) Netherlands: Lamisil | Terbinafine | Terbinafine A | Terbinafine alpharma | Terbinafine apotex | Terbinafine Aurobindo | Terbinafine cf | Terbinafine focus | Terbinafine Merck | Terbinafine PA | Terbinafine PCH | Terbinafine ratiopharm | Terbinafine sandoz | Terbinafine xiromed;
  • (NO) Norway: Lamisil | Terbinafin | Terbinafin Bmm Pharma | Terbinafin Copyfarm | Terbinafin hexal | Terbinafin orifarm | Terbinafine Aurobindo;
  • (NZ) New Zealand: Apo terbinafine | Deolate | Lamisil | Noumed terbinafine | Terbafin;
  • (PE) Peru: Dermoxyl | Finex | Fungustil | Funide | Lamidizol | Lamisil | Micofinal | Micostop | Micoterat | Micoterbin | Terbicel | Terbilab | Terbinafina | Terbisil | Terbispor | Terekol | Xilatril;
  • (PH) Philippines: Lamisil;
  • (PK) Pakistan: Ademac | Bina | Binafin | Binasil | Binzet | Caweda | Ckosil | Cutis | Daskil | Dermafin | Exinofin | Funasole | Funge | Fungi rid | Fungirid | Geosil | Lamicart | Lamisil | Lerbin | Logirid | Monofin | Mycoderm | Neoterbin | Novaterafine | Qtec | Retipro | Terabin | Terafin | Terbexin | Terbi | Terbicid | Terbiderm | Terbiderm forte | Terbifold | Terbilet | Terbimax | Terbimed | Terbin | Terbipearl | Terbisan | Terbiser | Terbisil | Terbitec | Terbix | Terbiz | Terbizor | Terbizor ds | Tersil | Tinabin | Tinadew | Tinea | Turbo;
  • (PL) Poland: Afugin | Erfin | Lamisil | Myconafine | Onymax | Terbinafin Bmm Pharma | Terbinafina | Terbinafine 1A Pharma | Terbinafine Aurobindo | Terbisil | Terbisil kid | Zelefion;
  • (PR) Puerto Rico: Lamisil | Terbinafine | Terbinafine HCL;
  • (PT) Portugal: Daskyl | Fungster | Lamisil | Terbin | Terbinafina | Terbinafina almus | Terbinafina parke davis | Terbinafina Stada | Termycol;
  • (PY) Paraguay: Finex | Lamisil | Limpex | Mircol | Terbiderm | Terbimax;
  • (QA) Qatar: Corbinal | Lamifen | Lamisil;
  • (RO) Romania: Terbisil;
  • (RU) Russian Federation: Atifin | Binafin | Bramisil | Cidocan | Exifine | Exiter | Fungoterbine | Lamisil | Medofloran | Onychon | Tebikur | Terbifin | Terbinafine | Terbinafine akrikhin | Terbinafine canon | Terbinafine hexal | Terbinafine mff | Terbinafine pfizer | Terbinafine sandoz | Terbinafine sar | Terbinafine teva | Terbinafine vertex | Terbinox | Terbisil | Termicon | Tigal sanovel;
  • (SA) Saudi Arabia: Lamifen | Lamisil | Negafen | Pms-terbinafin;
  • (SE) Sweden: Azurifin | Lamisil | Terbinafin 2care4 | Terbinafin actavis | Terbinafin Agp | Terbinafin Arrow | Terbinafin Bmm Pharma | Terbinafin Copyfarm | Terbinafin ebb | Terbinafin Galderma | Terbinafin hexal | Terbinafin Ivax | Terbinafin Mylan | Terbinafin Nordic drugs | Terbinafin Ratiopharm | Terbinafin Stada;
  • (SG) Singapore: Exifine | Lamisil;
  • (SI) Slovenia: Atifan | Lamisil | Terbinafine Arrow;
  • (SK) Slovakia: Brinaf | Lamisil | Mycodekan | Onychomed | Onychon | Terbinafin | Terbinafin actavis | Terbisil | Terfimed;
  • (SR) Suriname: Apo terbinafine | Terbinafine Mylan | Terbinafine sandoz | Terbisil;
  • (TH) Thailand: Lamisil;
  • (TN) Tunisia: Lamisil | Onycal | Terbinafine Winthrop | Terbisil | Tercyd | Tinasil;
  • (TR) Turkey: Corbinal | Laminox | Lamisil | Mikonafin | Mycocur | Tekfin | Terafin | Terbin | Terbisil | Terbonile | Terinateva | Terminus | Tigal;
  • (TW) Taiwan: Camisan | Fungitech | Lamisil | Lisim | Terfine | Terfung;
  • (UA) Ukraine: Binafin | Exifine | Fungotek | Lamicon | Lamiderm | Lamifen | Mycofin | Terbinafin kv | Terbinafine | Terbinorm | Terbinox;
  • (UG) Uganda: Fungisafe | Lamisil | Terafine | Terbiderm forte | Terbinaforce;
  • (UY) Uruguay: Lamisil | Terbimax | Terbinafina | Terfenam | Terfiren | Unex;
  • (VE) Venezuela, Bolivarian Republic of: Farbicil | Lamisil | Ofanthel | Perten | Terbicrym | Terbinafina | Terfex;
  • (ZA) South Africa: ADCO terbinafine | Arrow terbinafine | Binacil | Dermax | Finderm | Lamisil | Lamispor | Terbi Clear | Terbicil;
  • (ZM) Zambia: Lamisil | Sebifin | Terbane | Terbinaforce | Terbofin;
  • (ZW) Zimbabwe: Lamisil | Terbifin
  1. Abdel-Rahman SM, Herron J, Fallon-Friedlander S, Hauffe S, Horowitz A, Rivière GJ. Pharmacokinetics of terbinafine in young children treated for tinea capitis [published correction appears in Pediatr Infect Dis J. 2006;25(8):760]. Pediatr Infect Dis J. 2005;24(10):886-891. [PubMed 16220086]
  2. Abdel-Rahman SM, Nahata MC. Oral terbinafine: a new antifungal agent. Ann Pharmacother. 1997;31(4):445-456. [PubMed 9101008]
  3. Agarwal K, Manas DM, Hudson M. Terbinafine and fulminant hepatic failure. N Engl J Med. 1999;340(16):1292-1293. doi:10.1056/NEJM199904223401617 [PubMed 10215503]
  4. Aguilar C, Mueller KK. Reversible agranulocytosis associated with oral terbinafine in a pediatric patient. J Am Acad Dermatol. 2001;45(4):632-634. doi:10.1067/mjd.2001.117520 [PubMed 11568763]
  5. American Academy of Pediatrics (AAP). In: Kimberlin DW, Banerjee R, Barnett ED, Lynfield R, Sawyer MH, eds. Red Book: 2024-2027 Report of the Committee on Infectious Diseases. 33rd ed. American Academy of Pediatrics; 2024.
  6. American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. Red Book: 2018 Report of the Committee on Infectious Diseases. 31st ed. American Academy of Pediatrics; 2018.
  7. Amichai B, Grunwald MH. Adverse drug reactions of the new oral antifungal agents--terbinafine, fluconazole, and itraconazole. Int J Dermatol. 1998;37(6):410-415. [PubMed 9646122]
  8. Angello JT, Voytovich RM, Jan SA. A cost/efficacy analysis of oral antifungals indicated for the treatment of onychomycosis: griseofulvin, itraconazole, and terbinafine. Am J Manag Care. 1997;3(3):443-450. [PubMed 10173095]
  9. Balfour JA, Faulds D. Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial. Drugs. 1992;43(2):259-284. doi:10.2165/00003495-199243020-00010 [PubMed 1372222]
  10. Bar J, Samuelov L, Sprecher E, Mashiah J. Griseofulvin vs terbinafine for paediatric tinea capitis: When and for how long. Mycoses. 2019;62(10):949-953. doi:10.1111/myc.12970 [PubMed 31343780]
  11. Bell-Syer SE, Khan SM, Torgerson DJ. Oral treatments for fungal infections of the skin of the foot. Cochrane Database Syst Rev. 2012;10:CD003584. doi:10.1002/14651858.CD003584.pub2 [PubMed 23076898]
  12. Bellón T. Mechanisms of severe cutaneous adverse reactions: recent advances. Drug Saf. 2019;42(8):973-992. doi:10.1007/s40264-019-00825-2 [PubMed 31020549]
  13. Bhari N, Sahni K, Dev T, Sharma VK. Symmetrical drug-related intertriginous and flexural erythema (Baboon syndrome) induced by simultaneous exposure to oral and topical terbinafine. Int J Dermatol. 2017;56(8):e168-e170. doi:10.1111/ijd.13581 [PubMed 28244137]
  14. Bong JL, Lucke TW, Evans CD. Persistent impairment of taste resulting from terbinafine. Br J Dermatol. 1998;139(4):747-748. doi:10.1046/j.1365-2133.1998.02485.x [PubMed 9892929]
  15. Bonifaz A, Ramírez-Tamayo T, Saúl A. Tinea barbae (tinea sycosis): experience with nine cases. J Dermatol. 2003;30(12):898-903. [PubMed 14739517]
  16. Bradley JS, Nelson JD, Barnett ED, et al, eds. Nelson's Pediatric Microbial Therapy. 27th ed. American Academy of Pediatrics; 2021.
  17. Bradley JS, Nelson JD, Barnett ED, et al, eds. Nelson's Pediatric Antimicrobial Therapy. 30th ed. American Academy of Pediatrics; 2024.
  18. Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). Allergo J Int. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6 [PubMed 26120552]
  19. Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: part II. Lactation. J Am Acad Dermatol. 2014;70(3):417. [PubMed 24528912]
  20. Carstens J, Wendelboe P, Søgaard H, Thestrup-Pedersen K. Toxic epidermal necrolysis and erythema multiforme following therapy with terbinafine. Acta Derm Venereol. 1994;74(5):391-392. doi:10.2340/0001555574391392 [PubMed 7817681]
  21. Chapman SW, Pappas P, Kauffmann C, et al. Comparative evaluation of the efficacy and safety of two doses of terbinafine (500 and 1000 mg day(-1)) in the treatment of cutaneous or lymphocutaneous sporotrichosis. Mycoses. 2004;47(1-2):62-68. [PubMed 14998402]
  22. Chen X, Jiang X, Yang M, et al. Systemic antifungal therapy for tinea capitis in children. Cochrane Database Syst Rev. 2016;2016(5):CD004685. doi:10.1002/14651858.CD004685.pub3 [PubMed 27169520]
  23. Chen X, Jiang X, Yang M, et al. Systemic antifungal therapy for tinea capitis in children: an abridged Cochrane Review. J Am Acad Dermatol. 2017;76(2):368-374. doi:10.1016/j.jaad.2016.08.061 [PubMed 27816294]
  24. Chou WY, Hsu CJ. A case report of Majocchi's granuloma associated with combined therapy of topical steroids and adalimumab. Medicine (Baltimore). 2016;95(2):e2245. doi:10.1097/MD.0000000000002245 [PubMed 26765401]
  25. Cohen PR, Erickson CP, Calame A. Terbinafine-induced lichenoid drug eruption: case report and review of terbinafine-associated cutaneous adverse events. Dermatol Online J. 2020;26(7):13030/qt9jh9p0xp. [PubMed 32898398]
  26. Debruyne D, Coquerel A. Pharmacokinetics of antifungal agents in onychomycoses. Clin Pharmacokinet. 2001;40(6):441-472. doi:10.2165/00003088-200140060-00005 [PubMed 11475469]
  27. del Palacio Hernandez A, López Gómez S, González Lastra F, Moreno Palancar P, Iglesias Díez L. A comparative double-blind study of terbinafine (Lamisil) and griseofulvin in tinea corporis and tinea cruris. Clin Exp Dermatol. 1990;15(3):210-216. [PubMed 2194715]
  28. Doty RL, Haxel BR. Objective assessment of terbinafine-induced taste loss. Laryngoscope. 2005;115(11):2035-2037. doi:10.1097/01.MLG.0000181462.08683.0C [PubMed 16319619]
  29. Dwyer CM, White MI, Sinclair TS. Cholestatic jaundice due to terbinafine. Br J Dermatol. 1997;136(6):976-977. doi:10.1111/j.1365-2133.1997.tb03954.x [PubMed 9217846]
  30. Elewski BE, Cáceres HW, DeLeon L, et al. Terbinafine hydrochloride oral granules versus oral griseofulvin suspension in children with tinea capitis: results of two randomized, investigator-blinded, multicenter, international, controlled trials. J Am Acad Dermatol. 2008;59(1):41-54. doi:10.1016/j.jaad.2008.02.019 [PubMed 18378354]
  31. Elewski B, Tavakkol A. Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality. Ther Clin Risk Manag. 2005;1(4):299-306. [PubMed 18360572]
  32. El-Khalawany M, Shaaban D, Hassan H, et al. A multicenter clinicomycological study evaluating the spectrum of adult tinea capitis in Egypt. Acta Dermatovenerol Alp Pannonica Adriat. 2013;22(4):77-82. [PubMed 24336943]
  33. Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.
  34. Farag A, Taha M, Halim S. One-week therapy with oral terbinafine in cases of tinea cruris/corporis. Br J Dermatol. 1994;131(5):684-686. doi:10.1111/j.1365-2133.1994.tb04983.x [PubMed 7999601]
  35. Filanovsky K, Sigler E, Shvidel L. Thrombotic thrombocytopenic purpura following terbinafine therapy. J Clin Apher. 2015;30(1):58-59. doi:10.1002/jca.21359 [PubMed 25255772]
  36. Friedlander SF, Aly R, Krafchik B, et al; Tinea Capitis Study Group. Terbinafine in the treatment of Trichophyton tinea capitis: a randomized, double-blind, parallel-group, duration-finding study. Pediatrics. 2002;109(4):602-607. doi:10.1542/peds.109.4.602 [PubMed 11927703]
  37. Gega A, Ketsela G, Glavin FL, Soldevilla-Pico C, Schain D. Majocchi's granuloma after antithymocyte globulin therapy in a liver transplant patient. Transpl Infect Dis. 2010;12(2):143-145. doi:10.1111/j.1399-3062.2009.00454.x [PubMed 19761557]
  38. George A, Bhatia A, Kanish B, Williams A. Terbinafine induced pityriasis rosea-like eruption. Indian J Pharmacol. 2015;47(6):680-681. doi:10.4103/0253-7613.169574 [PubMed 26729964]
  39. Goday JJ, González-Güemes M, Yanguas I, Ilardia R, Soloeta R. Allergic contact dermatitis from naftifine in a child without cross-reaction to terbinafine. J Eur Acad Dermatol Venereol. 1998;11(1):72-73. [PubMed 9731972]
  40. Goldstein AO, Bhatia N. Onychomycosis: Management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 15, 2022.
  41. Goldstein AO, Goldstein BG. Dermatophyte (tinea) infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 7, 2024.
  42. Gupta AK, Adamiak A, Cooper EA. The efficacy and safety of terbinafine in children. J Eur Acad Dermatol Venereol. 2003;17(6):627-640. doi:10.1046/j.1468-3083.2003.00691.x [PubMed 14761128]
  43. Gupta AK, Cooper EA. Update in antifungal therapy of dermatophytosis. Mycopathologia. 2008;166(5-6):353-367. doi:10.1007/s11046-008-9109-0. [PubMed 18478357]
  44. Gupta AK, Foley KA, Versteeg SG. New antifungal agents and new formulations against dermatophytes. Mycopathologia. 2017;182(1-2):127-141. doi:10.1007/s11046-016-0045-0 [PubMed 27502503]
  45. Gupta AK, Lynde CW, Lauzon GJ, et al. Cutaneous adverse effects associated with terbinafine therapy: 10 case reports and a review of the literature. Br J Dermatol. 1998a;138(3):529-532. doi:10.1046/j.1365-2133.1998.02140.x [PubMed 9580815]
  46. Gupta AK, Paquet M, Simpson F, Tavakkol A. Terbinafine in the treatment of dermatophyte toenail onychomycosis: a meta-analysis of efficacy for continuous and intermittent regimens. J Eur Acad Dermatol Venereol. 2013;27(3):267-272. doi:10.1111/j.1468-3083.2012.04584.x [PubMed 22632057]
  47. Gupta AK, Porges AJ. Hypersensitivity syndrome reaction to oral terbinafine. Australas J Dermatol. 1998b;39(3):171-172. doi:10.1111/j.1440-0960.1998.tb01275.x [PubMed 9737044]
  48. Gupta AK, Shear NH. Terbinafine: an update. J Am Acad Dermatol. 1997a;37(6):979-988. doi:10.1016/s0190-9622(97)70076-8 [PubMed 9418768]
  49. Gupta AK, Sibbald RG, Lynde CW, et al. Onychomycosis in children: prevalence and treatment strategies. J Am Acad Dermatol. 1997b;36(3, pt 1):395-402. doi:10.1016/s0190-9622(97)80215-0 [PubMed 9091470]
  50. Gupta AK, Venkataraman M, Talukder M. Onychomycosis in older adults: prevalence, diagnosis, and management. Drugs Aging. 2022;39(3):191-198. doi:10.1007/s40266-021-00917-8 [PubMed 35102533]
  51. Hall M, Monka C, Krupp P, O'Sullivan D. Safety of oral terbinafine: results of a postmarketing surveillance study in 25,884 patients. Arch Dermatol. 1997;133(10):1213-1219. doi:10.1001/archderm.133.10.1213 [PubMed 9382559]
  52. Hawkins DM, Smidt AC. Superficial fungal infections in children. Pediatr Clin North Am. 2014;61(2):443-455. doi:10.1016/j.pcl.2013.12.003 [PubMed 24636655]
  53. Hill RC, Caplan AS, Elewski B, et al. Expert panel review of skin and hair dermatophytoses in an era of antifungal resistance. Am J Clin Dermatol. 2024;25(3):359-389. doi:10.1007/s40257-024-00848-1 [PubMed 38494575]
  54. Humbert H, Denouël J, Cabiac MD, Lakhdar H, Sioufi A. Pharmacokinetics of terbinafine and five known metabolites in children, after oral administration. Biopharm Drug Dispos. 1998;19(7):417-423. doi:10.1002/(sici)1099-081x(199810)19:7<417::aid-bdd111>3.0.co;2-t [PubMed 9818707]
  55. Ilkit M, Durdu M, Karakaş M. Majocchi's granuloma: a symptom complex caused by fungal pathogens. Med Mycol. 2012;50(5):449-457. doi:10.3109/13693786.2012.669503 [PubMed 22435879]
  56. Irimie M, Tătaru A, Oantă A, Moga M. In vitro susceptibility of dermatophytes isolated from patients with end-stage renal disease: a case-control study. Mycoses. 2014;57(3):129-134. doi:10.1111/myc.12114 [PubMed 23889207]
  57. Iverson SL, Uetrecht JP. Identification of a reactive metabolite of terbinafine: insights into terbinafine-induced hepatotoxicity. Chem Res Toxicol. 2001;14(2):175-181. doi:10.1021/tx0002029 [PubMed 11258966]
  58. Jackson JD. Infectious folliculitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 26, 2021.
  59. Janjua SA, Pastar Z, Iftikhar N, Ammad S. Intertriginous eruption induced by terbinafine: a review of baboon syndrome. Int J Dermatol. 2017;56(1):100-103. doi:10.1111/ijd.13292 [PubMed 27153516]
  60. Jensen JC. Clinical pharmacokinetics of terbinafine (Lamisil). Clin Exp Dermatol. 1989;14(2):110-113. doi:10.1111/j.1365-2230.1989.tb00904.x [PubMed 2689012]
  61. Jensen JC. Pharmacokinetics of Lamisil® in humans. J Dermatol Treat. 1990;1(suppl 2):15-18. doi:10.3109/09546639009089024
  62. Jones TC. Overview of the use of terbinafine (Lamisil) in children. Br J Dermatol. 1995;132(5):683-689. doi:10.1111/j.1365-2133.1995.tb00711.x [PubMed 7772471]
  63. Kauffman CA, Bustamante B, Chapman SW, Pappas PG; Infectious Diseases Society of America. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis. 2007;45(10):1255-1265. doi:10.1086/522765 [PubMed 17968818]
  64. Kaul S, Yadav S, Dogra S. Treatment of dermatophytosis in elderly, children, and pregnant women. Indian Dermatol Online J. 2017;8(5):310-318. doi:10.4103/idoj.IDOJ_169_17 [PubMed 28979861]
  65. Koumantaki E, Kakourou T, Rallis E, Riga P, Georgalla S. Doubled dose of oral terbinafine is required for Microsporum canis tinea capitis. Pediatr Dermatol. 2001;18(4):339-342. doi:10.1046/j.1525-1470.2001.01953.x [PubMed 11576412]
  66. Kovacs MJ, Alshammari S, Guenther L, Bourcier M. Neutropenia and pancytopenia associated with oral terbinafine. J Am Acad Dermatol. 1994;31(5, pt 1):806. doi:10.1016/s0190-9622(09)80049-2 [PubMed 7929931]
  67. Kramer ON, Albrecht J. Clinical presentation of terbinafine-induced severe liver injury and the value of laboratory monitoring: a critically appraised yopic. Br J Dermatol. 2017;177(5):1279-1284. doi:10.1111/bjd.15854 [PubMed 28762471]
  68. Kuo S, Sivamani RK. UVB-sensitive solar urticaria possibly associated with terbinafine. Dermatol Online J. 2014;20(3):doj_21753. [PubMed 24656267]
  69. Kyriakidis I, Tragiannidis A, Munchen S, Groll AH. Clinical hepatotoxicity associated with antifungal agents. Expert Opin Drug Saf. 2017;16(2):149-165. doi:10.1080/14740338.2017.1270264 [PubMed 27927037]
  70. Lamisil granules (terbinafine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; August 2016.
  71. Lamisil tablets (terbinafine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2019.
  72. Lamisil (terbinafine hydrochloride) [product monograph]. Dorval, Quebec, Canada: Novartis Consumer Canada Inc; May 2016.
  73. Lareb Netherlands Pharmacovigilance Centre. Terbinafine and smell alterations. https://databankws.lareb.nl/Downloads/KWB_2013_1_terbi.pdf. Published May 2013.
  74. Leung AK, Barankin B, Lam JM, Leong KF, Hon KL. Tinea pedis: an updated review. Drugs Context. 2023;12:2023-5-1. doi:10.7573/dic.2023-5-1 [PubMed 37415917]
  75. Lorentz K, Booken N, Goerdt S, Goebeler M. Subacute cutaneous lupus erythematosus induced by terbinafine: case report and review of literature. J Dtsch Dermatol Ges. 2008;6(10):823-828. doi:10.1111/j.1610-0387.2008.06806.x [PubMed 18564209]
  76. Miliszewski MA, Kirchhof MG, Sikora S, Papp A, Dutz JP. Stevens-Johnson syndrome and toxic epidermal necrolysis: an analysis of triggers and implications for improving prevention. Am J Med. 2016;129(11):1221-1225. doi:10.1016/j.amjmed.2016.03.022 [PubMed 27086495]
  77. Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: part I. Pregnancy. J Am Acad DermatolN. 2014;70(3):401. doi: 10.1016/j.jaad.2013.09.010. [PubMed 24528911]
  78. National Institute for Health and Care Excellence (NICE). Drug allergy: diagnosis and management. September 3, 2014. https://www.nice.org.uk/guidance/cg183. Accessed March 9, 2021.
  79. Nejjam F, Zagula M, Cabiac MD, Guessous N, Humbert H, Lakhdar H. Pilot study of terbinafine in children suffering from tinea capitis: evaluation of efficacy, safety and pharmacokinetics. Br J Dermatol. 1995;132(1):98-105. doi:10.1111/j.1365-2133.1995.tb08632.x [PubMed 7756158]
  80. Newland JG, Abdel-Rahman SM. Update on terbinafine with a focus on dermatophytoses. Clin Cosmet Investig Dermatol. 2009;2:49-63. doi:10.2147/ccid.s3690 [PubMed 21436968]
  81. Nicoletti P, Aithal GP, Bjornsson ES, et al. Association of liver injury from specific drugs, or groups of drugs, with polymorphisms in HLA and other genes in a genome-wide association study. Gastroenterology. 2017;152(5):1078-1089. doi:10.1053/j.gastro.2016.12.016 [PubMed 28043905]
  82. Olivier S, De Montjoye L, Tromme I, Baeck M. Two cases of annular acute generalized exanthematous pustulosis induced by terbinafine. Eur J Dermatol. 2018;28(2):236-238. doi:10.1684/ejd.2017.3199 [PubMed 29336314]
  83. Ornstein DL, Ely P. Reversible agranulocytosis associated with oral terbinafine for onychomycosis. J Am Acad Dermatol. 1998;39(6):1023-1024. doi:10.1016/s0190-9622(98)70284-1 [PubMed 9843023]
  84. Patel D, Castelo-Soccio LA, Rubin AI, Streicher JL. Laboratory monitoring during systemic terbinafine therapy for pediatric onychomycosis. JAMA Dermatol. 2017;153(12):1326-1327. doi:10.1001/jamadermatol.2017.4483 [PubMed 29188282]
  85. Perveze Z, Johnson MW, Rubin RA, et al. Terbinafine-induced hepatic failure requiring liver transplantation. Liver Transpl. 2007;13(1):162-164. doi:10.1002/lt.21034 [PubMed 17192859]
  86. Pierini AM, Soliani A, Hernandez M, Garcia-Diaz kR, Gonzalez MT, Santos P. Treatment of tinea capitis due to Microsporum canis with oral terbinafine: 40 cases. Pediatric Dermatology. 1998. Poster abstract P145.
  87. Raschi E, Poluzzi E, Koci A, Caraceni P, Ponti FD. Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database. World J Hepatol. 2014;6(8):601-612. doi:10.4254/wjh.v6.i8.601 [PubMed 25232453]
  88. Refer to manufacturer's labeling.
  89. Richert B, Uhoda I, De la Brassinne M. Hair loss after terbinafine treatment. Br J Dermatol. 2001;145(5):842. doi:10.1046/j.1365-2133.2001.04423.x [PubMed 11736917]
  90. Ross CL, Shevchenko A, Mollanazar NK, Hsu S, Motaparthi K. Acute generalized exanthematous pustulosis due to terbinafine. Dermatol Ther. 2018;31(4):e12617. doi:10.1111/dth.12617 [PubMed 29786933]
  91. Sarkar M, Rowland K, Koren G. Pregnancy outcomes following gestational exposure to terbinafine: a prospective comparative study. Abstracts of the Teratology Society 43rd Annual Meeting. June 21-26, 2003. Birth Defects Res A Clin Mol Teratol. 2003;67(5):313-394. [PubMed 12931704]
  92. Savin RC. Oral terbinafine versus griseofulvin in the treatment of moccasin-type tinea pedis. J Am Acad Dermatol. 1990;23(4, pt 2):807-809. doi:10.1016/0190-9622(90)70294-r [PubMed 2229529]
  93. Schrijvers R, Gilissen L, Chiriac AM, Demoly P. Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back. Clin Transl Allergy. 2015;5:31. doi:10.1186/s13601-015-0073-8 [PubMed 26339470]
  94. Shapiro M, Li LJ, Miller J. Terbinafine-induced neutropenia. Br J Dermatol. 1999;140(6):1196-1197. [PubMed 10354111]
  95. Shy R. Tinea corporis and tinea capitis. Pediatr Rev. 2007;28(5):164-174. doi:10.1542/pir.28-5-164 [PubMed 17473121]
  96. Sprenger AB, Purim KSM, Sprenger F, Queiroz-Telles F. A week of oral terbinafine pulse regimen every three months to treat all dermatophyte onychomycosis. J Fungi (Basel). 2019;5(3):82. doi:10.3390/jof5030082 [PubMed 31487828]
  97. Song JC, Deresinski S. Hepatotoxicity of antifungal agents. Curr Opin Investig Drugs. 2005;6(2):170-177. [PubMed 15751740]
  98. Stricker BH, Van Riemsdijk MM, Sturkenboom MC, Ottervanger JP. Taste loss to terbinafine: a case-control study of potential risk factors. Br J Clin Pharmacol. 1996;42(3):313-318. doi:10.1046/j.1365-2125.1996.04105.x [PubMed 8877021]
  99. Takahata Y, Hiruma M, Shiraki Y, Tokuhisa Y, Sugita T, Muto M. Treatment of dermatophyte onychomycosis with three pulses of terbinafine (500 mg day for a week). Mycoses. 2009;52(1):72-76. doi:10.1111/j.1439-0507.2008.01531.x [PubMed 18444971]
  100. Tausch I, Decroix J, Gwiedzdzinski Z, et al. Short-term itraconazole versus terbinafine in the treatment of tinea pedis or manus. Int J Dermatol. 1998;37(2):140-142. [PubMed 9542675]
  101. Terbinafine [prescribing information]. Memphis, TN: Northstar Rx LLC; November 2020.
  102. Terbinafine [prescribing information]. Princeton, NJ: OrchidPharma Inc; January 2022.
  103. Todd P, Halpern S, Munro DD. Oral terbinafine and erythema multiforme. Clin Exp Dermatol. 1995;20(3):247-248. doi:10.1111/j.1365-2230.1995.tb01314.x [PubMed 7671425]
  104. Treat JR. Tinea capitis: management. Connor RF, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed January 8, 2025.
  105. Trépanier EF, Amsden GW. Current issues in onychomycosis. Ann Pharmacother. 1998;32(2):204-214. doi:10.1345/aph.17006 [PubMed 9496407]
  106. Ungpakorn R, Ayutyanont T, Reangchainam S, Supanya S. Treatment of Microsporum spp. tinea capitis with pulsed oral terbinafine. Clin Exp Dermatol. 2004;29(3):300-303. doi:10.1111/j.1365-2230.2004.01493.x [PubMed 15115516]
  107. Vickers AE, Sinclair JR, Zollinger M, et al. Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions. Drug Metab Dispos. 1999;27(9):1029-1038. [PubMed 10460803]
  108. Voravutinon V. Oral treatment of tinea corporis and tinea cruris with terbinafine and griseofulvin: a randomized double blind comparative study. J Med Assoc Thai. 1993;76(7):388-393. [PubMed 8089640]
  109. Wang X, Yang Y, Li R, Yu J. Two cases of dermatophytic granuloma successfully treated with terbinafine. Mycopathologia. 2018;183(3):611-614. doi:10.1007/s11046-017-0237-2 [PubMed 29344845]
  110. Warshaw EM, Fett DD, Bloomfield HE, et al. Pulse versus continuous terbinafine for onychomycosis: a randomized, double-blind, controlled trial. J Am Acad Dermatol. 2005;53(4):578-584. doi:10.1016/j.jaad.2005.04.055 [PubMed 16198776]
  111. White JE, Perkins PJ, Evans EG. Successful 2-week treatment with terbinafine (Lamisil) for moccasin tinea pedis and tinea manuum. Br J Dermatol. 1991;125(3):260-262. doi:10.1111/j.1365-2133.1991.tb14752.x [PubMed 1911319]
  112. White SI, Bowen-Jones D. Toxic epidermal necrolysis induced by terbinafine in a patient on long-term anti-epileptics. Br J Dermatol. 1996;134(1):188-189. doi:10.1111/j.1365-2133.1996.tb07872.x [PubMed 8745918]
  113. Yadav P, Singal A, Pandhi D, Das S. Comparative efficacy of continuous and pulse dose terbinafine regimes in toenail dermatophytosis: a randomized double-blind trial. Indian J Dermatol Venereol Leprol. 2015;81(4):363-9. doi:10.4103/0378-6323.158634 [PubMed 26087080]
  114. Zaouak A, Ben Salem F, Charfi O, Hammami H, Fenniche S. Acute generalized exanthematous pustulosis induced by terbinafine in a child confirmed by patch testing. Int J Dermatol. 2019;58(2):e42-e43. doi:10.1111/ijd.14259 [PubMed 30255495]
  115. Zheng Y, Zhang J, Chen H, Lai W, Maibach HI. Terbinafine-induced lichenoid drug eruption. Cutan Ocul Toxicol. 2017;36(1):101-103. doi:10.3109/15569527.2016.1160101 [PubMed 26938740]
  116. Zhou S, Yang Y, Liu K, Huang S, Hu Y, Zhou X. A case report of widespread Majocchi's granuloma in a patient with systemic lupus erythematosus. Mycopathologia. 2017;182(5-6):577-581. doi:10.1007/s11046-017-0109-9 [PubMed 28083794]
  117. Zhou S, Bagga A. Rhabdomyolysis and acute kidney injury associated with terbinafine use: a case report. Can J Kidney Health Dis. 2020;7:2054358120951371. doi:10.1177/2054358120951371 [PubMed 33149920]
Topic 15936 Version 412.0